drugset / Trial / NCT02954991
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
Timeline
- Start
- 2016-11-07
- Primary completion
- 2021-11-04
- Completion
- 2021-11-04
Outcome
Outcome not reported
Stopped (Business): “This study was terminated as a result of Sponsor portfolio reprioritization.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glesatinib | Small molecule | — | Oral |
| Subject | Mocetinostat | Small molecule | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Sitravatinib | Small molecule | — | Oral |